Answers are grounded in this paper and cite their sources.
Neuroinjury, including traumatic brain injury, ischemic and hemorrhagic stroke (intracerebral hemorrhage), subarachnoid hemorrhage and spinal cord injury, collectively is a significant biomedical problem worldwide. Yet there are few therapeutic options available. We submit that mass spectrometry-based proteomic approach can have a potentially high impact in biomarkers discovery and drug target identification for various forms of CNS injury. This review provides an outline of the most important mass spectrometry-based proteomic application tools (differential, quantitative, and imaging mass spectrometry analysis) being used for translational neuroinjury research from animal studies to clinical studies and validations.
No takes yet. Share an insight, caveat, or question.
Moghieb et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: